Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somapacitan once weekly versus daily Norditropin in children with short stature disorders
NL-OMON55970Phase 3Recruiting
- Sponsor
- Novo Nordisk
- Start
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of somapacitan and somatropin in growth disorder, Small for gestational age (SGA), Turner syndrome (TS) and 2 more (10 arms), sponsored by Novo Nordisk. Primary endpoint: Height velocity. Started Jun 2023; status: recruiting.
02
Drugs
somapacitansomatropin
03
Conditions
growth disorderSmall for gestational age (SGA)Turner syndrome (TS)Noonan syndromeIdiopathic Short Stature (ISS)
Beyond the preview
Go deeper on NL-OMON55970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55970.